BAY 2701439
Phase 2
BayerBAY 2701439 is one of 31 therapeutic programs targeting Ocular Hypertension. It is currently in Phase 2.
2
Indications
0
Total Trials
0
Active Trials
30
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
187 competitors in Ocular Hypertension
#DrugCompanyPhaseTrials
1Alphagan
NovartisPhase 3
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Azopt
NovartisPhase 3
Ocupress
AbbViePhase 3
Krytantek
AbbViePhase 3
LUMIGAN
AbbViePhase 3
Bimatoprost/timolol
AbbViePhase 3
Preservative-Free Tafluprost
Merck & Co.Phase 3
PRO-122
LLaboratorios Sophia S.A de C.V.
Phase 3
Reference - LUMIGAN
AAmneal Pharmaceuticals, LLC
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for BAY 2701439. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2
- Company